News Search Results
Mar 06, 2026, 07:03 ET CARsgen Therapeutics Announces 2025 Annual Results
development: KJ-C2320 against CD38 for acute myeloid leukemia (AML); KJ-C2526 against NKG2DL for AML, other malignancies and senescence; CT1390B against CLL1 for AML; KJ-C2527 against Claudin18.2 for gastric cancer.On February 25, 2025, CARsgen has entered into the agreements with an investment fund
More news about: CARsgen Therapeutics
Mar 01, 2026, 19:00 ET Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
represents an important advancement for patients with relapsed or refractory CLL. The BRUIN CLL‑321 study demonstrated its therapeutic potential in CLL/SLL. We believe it will offer an important treatment option for patients with CLL/SLL in China and help meet the needs of long‑term disease management in
More news about: Innovent Biologics
Feb 20, 2026, 02:00 ET U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
acalabrutinib for use as a front-line therapy in CLL, patients in the USA now have an all oral, time-limited option that can be important for many in choosing their treatment," said Dr. Brian Koffman, co-founder and chief medical officer emeritus, CLL Society. "CLL Society is pleased to see the number of choices
More news about: AbbVie
Feb 16, 2026, 10:15 ET CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™
for the largest share of the CAR T-cell therapy market. Bristol Myers Squibb expanded Breyanzi's FDA approval in 2024 to chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Building on the initial success of CD19 CAR T-cell therapies in treating acute lymphoblastic leukemia (ALL) and
More news about: MarketsandMarkets
Feb 12, 2026, 17:31 ET BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsight
with challenging hematologic malignancies, such as CLL and AML.Venetoclax, the first FDA-approved specific inhibitor of BCL-2, is highly effective as monotherapy for CLL and mantle cell lymphoma (MCL) and is now part of frontline CLL treatment.Venetoclax demonstrates rapid and
More news about: DelveInsight Business Research, LLP
Feb 05, 2026, 21:04 ET 亞盛醫藥BTK降解劑APG-3288新藥臨床申請（IND）獲CDE許可，全球臨床開發再提速
Medicine, 2022. 386(8): p. 735-743.[3]. Zhang, D., et al., NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts. Blood, 2023. 141(13): p. 1584-1596.關於亞盛醫藥亞盛醫藥是一家綜合性的全球生物醫藥企業，致力於研發創新藥，以解決腫瘤等領域全球患者尚未滿足的臨床需求。2019年10
More news about: 亞盛醫藥
Feb 04, 2026, 06:45 ET Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance
indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor (
More news about: Eli Lilly and Company
Jan 14, 2026, 20:16 ET 亞盛醫藥精彩亮相第44屆摩根大通醫療健康年會主會場，「全球創新」戰略邁入新階段
單藥在對BTKi耐藥的重度經治R/R CLL/SLL患者中展現了顯著且持久的療效，且安全性可控，未觀察到任何腫瘤溶解綜合征（TLS）病例。值得一提的是，該研究共入組77例患者(100%為 BTKi治療耐藥/不耐受患者
More news about: 亞盛醫藥
Jan 14, 2026, 10:52 ET Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
registration in relapsed/refractory chronic lymphocytic leukemia. The company initiated the DAYBreak CLL-201 pivotal Phase 2 study in October 2025 and plans to initiate the confirmatory Phase 3 trial DAYBreak CLL-306 in 2026, comparing bexobrutideg monotherapy to pirtobrutinib."2025 was a defining year
More news about: Equity Insider
Jan 06, 2026, 20:30 ET 亞盛醫藥BTK降解劑APG-3288的新藥臨床申請（IND）獲美國FDA許可
[4]. Zhang, D., et al., NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts. Blood, 2023. 141(13): p. 1584-1596.[5]. Wu, Y., et al., Translational
More news about: 亞盛醫藥
Jan 06, 2026, 03:19 ET Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
lymphomaA BTK-targeting chimeric degradation activation compound (CDAC), administered once daily orally to treat relapsed or refractory CLL and SLL, also under investigation for Waldenstrom's macroglobulinemia, other B-cell malignancies, including MCL and FL and chronic spontaneous urticaria.
More news about: Clarivate Plc
Jan 06, 2026, 03:07 ET Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
lymphomaA BTK-targeting chimeric degradation activation compound (CDAC), administered once daily orally to treat relapsed or refractory CLL and SLL, also under investigation for Waldenstrom's macroglobulinemia, other B-cell malignancies, including MCL and FL and chronic spontaneous urticaria.
More news about: Clarivate Plc
Jan 05, 2026, 07:00 ET RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
sufficient for approval and, if approved, may not be a commercial success; the risk that opaganib may not replicate its potential to mitigate resistance in CLL therapy; the risk that the strategic transaction with Cumberland will not bring the currently anticipated benefits to RedHill's global Talicia business
More news about: RedHill Biopharma Ltd.
Dec 19, 2025, 07:44 ET Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
new data from its Phase 1b/2 EPCORE CLL-1 trial demonstrating epcoritamab's effectiveness as both monotherapy and in combination regimens for patients with Richter transformation, a rare and
More news about: USA News Group
Dec 15, 2025, 07:00 ET RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
activation and proliferation of venetoclax-resistant CLL cancer cells and resensitize previously resistant CLL cells2,3New in vivo study shows adding opaganib, a potent SPHK2 inhibitor, to venetoclax reduces CLL cell (CD19⁺, CD5⁺) counts by 50% compared to controls
More news about: RedHill Biopharma Ltd.
Dec 09, 2025, 07:30 ET Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
progression-free survival benefit, early overall survival trend and safety profile observed in BRUIN CLL-313 offer highly compelling evidence for the potential role of pirtobrutinib in treatment-naïve CLL."BRUIN CLL-313 is the first prospective, randomized Phase 3 study examining the efficacy and safety of
More news about: Eli Lilly and Company
Dec 09, 2025, 07:30 ET Pirtobrutinib Outperforms Bendamustine Plus Rituximab for Previously Untreated CLL/SLL
combination treatment for CLL/SLL.BTK inhibitors work by blocking the BTK enzyme, which plays a role in B cell growth and proliferation. Pirtobrutinib is developed to overcome the tendency for cancer cells to become resistant to previous-generation covalent BTK inhibitors.CLL and SLL are slow-growing
More news about: American Society of Hematology
Dec 09, 2025, 05:00 ET Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025
JAK1 inhibition in this high-risk disease.BirelentinibChronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a malignancy originating from mature B-cell non-Hodgkin lymphoma (B-NHL). While Bruton's tyrosine kinase (BTK) inhibitors have transformed the
More news about: Dizal Pharmaceutical
Dec 07, 2025, 16:30 ET Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
for people living with CLL or SLL across various disease settings."As part of the Late-Breaking Abstract Session on Dec. 9, Lilly will also share results from the Phase 3 BRUIN CLL-313 study of pirtobrutinib versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL without del(17p). These
More news about: Eli Lilly and Company
Dec 07, 2025, 07:30 ET Studies Point to a Growing Role for New Therapies and Immunotherapies in Treating Blood Cancers
choice in both the treatment-naive and relapsed/refractory settings."CLL and SLL are slow-growing forms of non-Hodgkin lymphoma that develop when lymphocytes grow out of control and abnormal B cells build up in bone marrow (CLL) or lymph nodes (SLL). BTK inhibitors work by blocking the BTK enzyme, which
More news about: American Society of Hematology
Dec 07, 2025, 03:58 ET 【直擊2025 ASH】突破BTKi耐藥和複雜核型的困境！亞盛醫藥口頭報告利生妥®中國關鍵註冊研究數據
利生妥®單藥在對BTKi耐藥的重度經治R/R CLL/SLL患者中展現了顯著且持久的療效及可控的安全性，充分說明其有望為R/R CLL/SLL患者帶來新的治療選擇利生妥®在對BTKi耐藥的重度經治R/R CLL/SLL患者中的客觀緩解率（ORR）為62.5%，其中近半數患者為伴染色體複雜核型既往接受BTKi，且重度經治的R/R
More news about: 亞盛醫藥
Dec 06, 2025, 08:30 ET Advances in Technology Help Improve Safety and Access to Blood Cancer Therapies
targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment
More news about: American Society of Hematology
Dec 04, 2025, 03:00 ET iOnctura initiates Phase I/II trial in patients with myelofibrosis ahead of new non-clinical data at ASH
related to MF, trials in progress posters for the ongoing investigations of roginolisib in peripheral T-cell lymphoma and chronic lymphocytic leukemia (CLL) will also be presented at ASH.iOnctura poster presentations at the 67th ASH Annual Meeting in Orlando, Florida, USA:1.
More news about: iOnctura
Dec 03, 2025, 12:59 ET U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with a covalent BTK inhibitorThis expanded indication represents a substantial increase in the number of CLL/SLL patients who may benefit
More news about: Eli Lilly and Company
Dec 03, 2025, 10:00 ET Florida Cancer Specialists & Research Institute Contributing To Breakthroughs In Treatment of Blood Cancers & Disorders
the U.S. Food & Drug Administration (FDA) in 2023 for mantle cell lymphoma (MCL), followed shortly by approvals for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). In 2024, the FDA approved revumenib—a revolutionary therapy for relapsed or refractory acute leukemia—after it
More news about: Florida Cancer Specialists & Research Institute